Advancement in Epilepsy Pharmacotherapy: An Insight into the Pharmacophoric Approaches of Recent Drugs

Jacoby, A.; Snape, D.; Baker, G. Epilepsy and social identity: The stigma of a chronic neurological disorder. Lancet Neurol., 2005, 4(3), 171-178.
[http://dx.doi.org/10.1016/S1474-4422(05)70020-X] [PMID: 15721827]

Savage, N. Epidemiology: The complexities of epilepsy. Nature, 2014, 511(7508), S2-S3.
[http://dx.doi.org/10.1038/511S2a] [PMID: 25019123]

Thompson, P.M.; Jahanshad, N.; Ching, C.R.K.; Salminen, L.E.; Thomopoulos, S.I.; Bright, J.; Baune, B.T.; Bertolín, S.; Bralten, J.; Bruin, W.B.; Bülow, R.; Chen, J.; Chye, Y.; Dannlowski, U.; de Kovel, C.G.F.; Donohoe, G.; Eyler, L.T.; Faraone, S.V.; Favre, P.; Filippi, C.A.; Frodl, T.; Garijo, D.; Gil, Y.; Grabe, H.J.; Grasby, K.L.; Hajek, T.; Han, L.K.M.; Hatton, S.N.; Hilbert, K.; Ho, T.C.; Holleran, L.; Homuth, G.; Hosten, N.; Houenou, J.; Ivanov, I.; Jia, T.; Kelly, S.; Klein, M.; Kwon, J.S.; Laansma, M.A.; Leerssen, J.; Lueken, U.; Nunes, A.; Neill, J.O.; Opel, N.; Piras, F.; Piras, F.; Postema, M.C.; Pozzi, E.; Shatokhina, N.; Soriano-Mas, C.; Spalletta, G.; Sun, D.; Teumer, A.; Tilot, A.K.; Tozzi, L.; van der Merwe, C.; Van Someren, E.J.W.; van Wingen, G.A.; Völzke, H.; Walton, E.; Wang, L.; Winkler, A.M.; Wittfeld, K.; Wright, M.J.; Yun, J.Y.; Zhang, G.; Zhang-James, Y.; Adhikari, B.M.; Agartz, I.; Aghajani, M.; Aleman, A.; Althoff, R.R.; Altmann, A.; Andreassen, O.A.; Baron, D.A.; Bartnik-Olson, B.L.; Marie Bas-Hoogendam, J.; Baskin-Sommers, A.R.; Bearden, C.E.; Berner, L.A.; Boedhoe, P.S.W.; Brouwer, R.M.; Buitelaar, J.K.; Caeyenberghs, K.; Cecil, C.A.M.; Cohen, R.A.; Cole, J.H.; Conrod, P.J.; De Brito, S.A.; de Zwarte, S.M.C.; Dennis, E.L.; Desrivieres, S.; Dima, D.; Ehrlich, S.; Esopenko, C.; Fairchild, G.; Fisher, S.E.; Fouche, J.P.; Francks, C.; Frangou, S.; Franke, B.; Garavan, H.P.; Glahn, D.C.; Groenewold, N.A.; Gurholt, T.P.; Gutman, B.A.; Hahn, T.; Harding, I.H.; Hernaus, D.; Hibar, D.P.; Hillary, F.G.; Hoogman, M.; Hulshoff Pol, H.E.; Jalbrzikowski, M.; Karkashadze, G.A.; Klapwijk, E.T.; Knickmeyer, R.C.; Kochunov, P.; Koerte, I.K.; Kong, X.Z.; Liew, S.L.; Lin, A.P.; Logue, M.W.; Luders, E.; Macciardi, F.; Mackey, S.; Mayer, A.R.; McDonald, C.R.; McMahon, A.B.; Medland, S.E.; Modinos, G.; Morey, R.A.; Mueller, S.C.; Mukherjee, P.; Namazova-Baranova, L.; Nir, T.M.; Olsen, A.; Paschou, P.; Pine, D.S.; Pizzagalli, F.; Rentería, M.E.; Rohrer, J.D.; Sämann, P.G.; Schmaal, L.; Schumann, G.; Shiroishi, M.S.; Sisodiya, S.M.; Smit, D.J.A.; Sønderby, I.E.; Stein, D.J.; Stein, J.L.; Tahmasian, M.; Tate, D.F.; Turner, J.A.; van den Heuvel, O.A.; van der Wee, N.J.A.; van der Werf, Y.D.; van Erp, T.G.M.; van Haren, N.E.M.; van Rooij, D.; van Velzen, L.S.; Veer, I.M.; Veltman, D.J.; Villalon-Reina, J.E.; Walter, H.; Whelan, C.D.; Wilde, E.A.; Zarei, M.; Zelman, V. ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries. Transl. Psychiatry, 2020, 10(1), 100.
[http://dx.doi.org/10.1038/s41398-020-0705-1] [PMID: 32198361]

Kachru, R.; Perry-Lunardo, C.; Thompson, L.A. CBD use in children—miracle, myth, or mystery? JAMA Pediatr., 2021, 175(6), 652.
[http://dx.doi.org/10.1001/jamapediatrics.2021.0367] [PMID: 33900374]

Goodman, A.M.; Szaflarski, J.P. Recent advances in neuroimaging of epilepsy. Neurotherapeutics, 2021, 18(2), 811-826.
[http://dx.doi.org/10.1007/s13311-021-01049-y] [PMID: 33942270]

Kaestner, E.; Reyes, A.; Chen, A.; Rao, J.; Macari, A.C.; Choi, J.Y.; Qiu, D.; Hewitt, K.; Wang, Z.I.; Drane, D.L.; Hermann, B.; Busch, R.M.; Punia, V.; McDonald, C.R. Atrophy and cognitive profiles in older adults with temporal lobe epilepsy are similar to mild cognitive impairment. Brain, 2021, 144(1), 236-250.
[http://dx.doi.org/10.1093/brain/awaa397] [PMID: 33279986]

Chen, Q.; Yang, P.; Lin, Q.; Pei, J.; Jia, Y.; Zhong, Z.; Wang, S. Effects of scorpion venom heat-resistant peptide on the hippocampal neurons of kainic acid-induced epileptic rats. Braz. J. Med. Biol. Res., 2021, 54(5), e10717.
[http://dx.doi.org/10.1590/1414-431x202010717] [PMID: 33825777]

Wu, X.; Dong, W.; Li, H.; Yang, X.; Jin, Y.; Zhang, Z.; Jiang, Y. CYP2C9*3/*3 gene expression affects the total and free concentrations of valproic acid in pediatric patients with epilepsy. Pharm. Genomics Pers. Med., 2021, 14, 417-430.
[http://dx.doi.org/10.2147/PGPM.S301893] [PMID: 33859491]

Sanabria, E.; Cuenca, R.E.; Esteso, M.Á.; Maldonado, M. Benzodiazepines: Their use either as essential medicines or as toxics substances. Toxics, 2021, 9(2), 25.
[http://dx.doi.org/10.3390/toxics9020025] [PMID: 33535485]

Suroto, S.; Diansari, Y.; Marisdina, S. Does electroencephalography result affect the success of treatment for epilepsy patients? Bioscientia Medicina. Journal of Biomedicine and Translational Research., 2021, 5(1), 224-231.

Kumar, R.; Arora, R.; Sarangi, S.C.; Ganeshan, N.S.; Agarwal, A.; Kaleekal, T.; Gupta, Y.K. Pharmacodynamic and pharmacokinetic interactions of hydroalcoholic leaf extract of Centella asiatica with valproate and phenytoin in experimental models of epilepsy in rats. J. Ethnopharmacol., 2021, 270, 113784.
[http://dx.doi.org/10.1016/j.jep.2021.113784] [PMID: 33429032]

Korczyn, A.D.; Schachter, S.C.; Amlerova, J.; Bialer, M.; van Emde Boas, W.; Brázdil, M.; Brodtkorb, E.; Engel, J., Jr; Gotman, J.; Komárek, V.; Leppik, I.E.; Marusic, P.; Meletti, S.; Metternich, B.; Moulin, C.J.A.; Muhlert, N.; Mula, M.; Nakken, K.O.; Picard, F.; Schulze-Bonhage, A.; Theodore, W.; Wolf, P.; Zeman, A.; Rektor, I. Third international congress on epilepsy, brain and mind: Part 1. Epilepsy Behav., 2015, 50, 116-137.
[http://dx.doi.org/10.1016/j.yebeh.2015.06.044] [PMID: 26276417]

Solli, E.; Colwell, N.A.; Say, I.; Houston, R.; Johal, A.S.; Pak, J.; Tomycz, L. Deciphering the surgical treatment gap for drug‐resistant epilepsy (DRE): A literature review. Epilepsia, 2020, 61(7), 1352-1364.
[http://dx.doi.org/10.1111/epi.16572] [PMID: 32558937]

Davis, P.; Gaitanis, J. Neuromodulation for the treatment of epilepsy: A review of current approaches and future directions. Clin. Ther., 2020, 42(7), 1140-1154.
[http://dx.doi.org/10.1016/j.clinthera.2020.05.017] [PMID: 32620340]

Sharma, V.; Joshi, S.; Majee, C. Receptor Binding Domain and accessible Treatments for Corona Virus. RE:view, 2020, (1), 2708-2713.

Saggio, M.L.; Crisp, D.; Scott, J.M.; Karoly, P.; Kuhlmann, L.; Nakatani, M.; Murai, T.; Dümpelmann, M.; Schulze-Bonhage, A.; Ikeda, A.; Cook, M.; Gliske, S.V.; Lin, J.; Bernard, C.; Jirsa, V.; Stacey, W.C. A taxonomy of seizure dynamotypes. eLife, 2020, 9, e55632.
[http://dx.doi.org/10.7554/eLife.55632] [PMID: 32691734]

Harcourt, S. The neuropsychology of epilepsy and suicide: A review. Aggress. Violent. Behav., 2020, 54, 101411.
[http://dx.doi.org/10.1016/j.avb.2020.101411]

Li, X.; Song, Y.; Xiao, G.; Xie, J.; Dai, Y.; Xing, Y.; He, E.; Wang, Y.; Xu, S.; Zhang, L.; Yu, D.; Tao, T.H.; Cai, X. Flexible electrocorticography electrode array for epileptiform electrical activity recording under glutamate and GABA modulation on the primary somatosensory cortex of rats. Micromachines (Basel), 2020, 11(8), 732.
[http://dx.doi.org/10.3390/mi11080732] [PMID: 32751055]

Cepeda, C.; Levinson, S.; Nariai, H.; Yazon, V.W.; Tran, C.; Barry, J.; Oikonomou, K.D.; Vinters, H.V.; Fallah, A.; Mathern, G.W.; Wu, J.Y. Pathological high frequency oscillations associate with increased GABA synaptic activity in pediatric epilepsy surgery patients. Neurobiol. Dis., 2020, 134, 104618.
[http://dx.doi.org/10.1016/j.nbd.2019.104618] [PMID: 31629890]

Simeone, T.A.; Simeone, K.A.; Samson, K.K.; Kim, D.Y.; Rho, J.M. Loss of the Kv1.1 potassium channel promotes pathologic sharp waves and high frequency oscillations in in vitro hippocampal slices. Neurobiol. Dis., 2013, 54, 68-81.
[http://dx.doi.org/10.1016/j.nbd.2013.02.009] [PMID: 23466697]

Healy, D.G.; Falchi, M.; O’Sullivan, S.S.; Bonifati, V.; Durr, A.; Bressman, S.; Brice, A.; Aasly, J.; Zabetian, C.P.; Goldwurm, S.; Ferreira, J.J.; Tolosa, E.; Kay, D.M.; Klein, C.; Williams, D.R.; Marras, C.; Lang, A.E.; Wszolek, Z.K.; Berciano, J.; Schapira, A.H.V.; Lynch, T.; Bhatia, K.P.; Gasser, T.; Lees, A.J.; Wood, N.W. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: A case-control study. Lancet Neurol., 2008, 7(7), 583-590.
[http://dx.doi.org/10.1016/S1474-4422(08)70117-0] [PMID: 18539534]

García, H.H.; Evans, C.A.W.; Nash, T.E.; Takayanagui, O.M.; White, A.C., Jr; Botero, D.; Rajshekhar, V.; Tsang, V.C.W.; Schantz, P.M.; Allan, J.C.; Flisser, A.; Correa, D.; Sarti, E.; Friedland, J.S.; Martinez, S.M.; Gonzalez, A.E.; Gilman, R.H.; Del Brutto, O.H. Current consensus guidelines for treatment of neurocysticercosis. Clin. Microbiol. Rev., 2002, 15(4), 747-756.
[http://dx.doi.org/10.1128/CMR.15.4.747-756.2002] [PMID: 12364377]

Menendez de la Prida, L.; Trevelyan, A.J. Cellular mechanisms of high frequency oscillations in epilepsy: On the diverse sources of pathological activities. Epilepsy Res., 2011, 97(3), 308-317.
[http://dx.doi.org/10.1016/j.eplepsyres.2011.02.009] [PMID: 21482073]

Nash, T.E.; Singh, G.; White, A.C.; Rajshekhar, V.; Loeb, J.A.; Proaño, J.V.; Takayanagui, O.M.; Gonzalez, A.E.; Butman, J.A.; DeGiorgio, C.; Del Brutto, O.H.; Delgado-Escueta, A.; Evans, C.A.W.; Gilman, R.H.; Martinez, S.M.; Medina, M.T.; Pretell, E.J.; Teale, J.; Garcia, H.H. Treatment of neurocysticercosis: Current status and future research needs. Neurology, 2006, 67(7), 1120-1127.
[http://dx.doi.org/10.1212/01.wnl.0000238514.51747.3a] [PMID: 17030744]

Gulyás, A.I.; Freund, T.T. Generation of physiological and pathological high frequency oscillations: The role of perisomatic inhibition in sharp-wave ripple and interictal spike generation. Curr. Opin. Neurobiol., 2015, 31, 26-32.
[http://dx.doi.org/10.1016/j.conb.2014.07.020] [PMID: 25128735]

Sotelo, J.; Jung, H. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin. Pharmacokinet., 1998, 34(6), 503-515.
[http://dx.doi.org/10.2165/00003088-199834060-00006] [PMID: 9646011]

Luo, C.; Kuner, T.; Kuner, R. Synaptic plasticity in pathological pain. Trends Neurosci., 2014, 37(6), 343-355.
[http://dx.doi.org/10.1016/j.tins.2014.04.002] [PMID: 24833289]

Colli, B.O.; Martelli, N.; Assirati, J.A., Jr; Machado, H.R.; Forjaz, S.V. Results of surgical treatment of neurocysticercosis in 69 cases. J. Neurosurg., 1986, 65(3), 309-315.
[http://dx.doi.org/10.3171/jns.1986.65.3.0309] [PMID: 3734881]

Carpio, A.; Kelvin, E.A.; Bagiella, E.; Leslie, D.; Leon, P.; Andrews, H.; Hauser, W.A. Effects of albendazole treatment on neurocysticercosis: A randomised controlled trial. J. Neurol. Neurosurg. Psychiatry, 2008, 79(9), 1050-1055.
[http://dx.doi.org/10.1136/jnnp.2008.144899] [PMID: 18495737]

Le Van Quyen, M.; Khalilov, I.; Ben-Ari, Y. The dark side of high-frequency oscillations in the developing brain. Trends Neurosci., 2006, 29(7), 419-427.
[http://dx.doi.org/10.1016/j.tins.2006.06.001] [PMID: 16793147]

Sparks, F.; Liao, Z.; Li, W.; Soltesz, I.; Losonczy, A. Adult-born granule cells support pathological microcircuits in the chronically epileptic dentate gyrus. bioRxiv, 2020.
[http://dx.doi.org/10.1101/2020.05.01.072173]

Garcia, L.; D’Alessandro, G.; Bioulac, B.; Hammond, C. High-frequency stimulation in Parkinson’s disease: More or less? Trends Neurosci., 2005, 28(4), 209-216.
[http://dx.doi.org/10.1016/j.tins.2005.02.005] [PMID: 15808356]

Viswanatha, G.L.; Sowmya, G.P.; Shylaja, H.; Moolemath, Y. Methanolic stem extract of Colebrookea oppositifolia attenuates epilepsy in experimental animal models: Possible role of GABA pathways. Journal of Biologically Active Products from Nature, 2020, 10(1), 44-58.
[http://dx.doi.org/10.1080/22311866.2020.1740109]

Sharma, V.; Majee, C.; Saxena, S.; Kumar, R. Weapon against epilepsy: acorus calamus, it’s phytochemistry, ethnopharmacology, and pharmacological actions. Int J Pharmaceut Res, 2021, 13(1), 2613-2627.

Varnado, S.; Price, D. Basics of modern epilepsy classification and terminology. Curr. Probl. Pediatr. Adolesc. Health Care, 2020, 50(11), 100891.
[http://dx.doi.org/10.1016/j.cppeds.2020.100891] [PMID: 33153903]

Yaria, J.O.; Ogunniyi, A. Calibration of the epilepsy questionnaire for use in a low-resource setting. J. Environ. Public Health, 2020, 2020, 1-8.
[http://dx.doi.org/10.1155/2020/5193189] [PMID: 32934658]

Medina, M.T.; Aguilar-Estrada, R.L.; Alvarez, A.; Durón, R.M.; Martínez, L.; Dubón, S.; Estrada, A.L.; Zúniga, C.; Cartagena, D.; Thompson, A.; Ramirez, E.; Banegas, L.; Osorio, J.R.; Delgado-Escueta, A.V.; Collins, J.S.; Holden, K.R. Reduction in rate of epilepsy from neurocysticercosis by community interventions: The Salamá, Honduras Study. Epilepsia, 2011, 52(6), 1177-1185.
[http://dx.doi.org/10.1111/j.1528-1167.2010.02945.x] [PMID: 21275975]

Patel, A.A.; Ciccone, O.; Njau, A.; Shanungu, S.; Grollnek, A.K.; Fredrick, F.; Hodgeman, R.; Sideridis, G.D.; Kapur, K.; Harini, C.; Kija, E.; Peters, J.M. A pediatric epilepsy diagnostic tool for use in resource-limited settings: A pilot study. Epilepsy Behav., 2016, 59, 57-61.
[http://dx.doi.org/10.1016/j.yebeh.2016.03.019] [PMID: 27088519]

Carpio, A.; Hauser, W.A. Epilepsy in the developing world. Curr. Neurol. Neurosci. Rep., 2009, 9(4), 319-326.
[http://dx.doi.org/10.1007/s11910-009-0048-z] [PMID: 19515285]

Elsayed, M.; El-Sayed, N.; Badi, S.; Ahmed, M. Factors affecting adherence to antiepileptic medications among Sudanese individuals with epilepsy: A cross-sectional survey. J. Family Med. Prim. Care, 2019, 8(7), 2312-2317.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_405_19] [PMID: 31463248]

Steudle, F.; Rehman, S.; Bampali, K.; Simeone, X.; Rona, Z.; Hauser, E.; Schmidt, W.M.; Scholze, P.; Ernst, M. A novel de novo variant of GABRA1 causes increased sensitivity for GABA in vitro. Sci. Rep., 2020, 10(1), 2379.
[http://dx.doi.org/10.1038/s41598-020-59323-6] [PMID: 32047208]

Pfisterer, U.; Petukhov, V.; Demharter, S.; Meichsner, J.; Thompson, J.J.; Batiuk, M.Y.; Asenjo-Martinez, A.; Vasistha, N.A.; Thakur, A.; Mikkelsen, J.; Adorjan, I.; Pinborg, L.H.; Pers, T.H.; von Engelhardt, J.; Kharchenko, P.V.; Khodosevich, K. Identification of epilepsy-associated neuronal subtypes and gene expression underlying epileptogenesis. Nat. Commun., 2020, 11(1), 5038.
[http://dx.doi.org/10.1038/s41467-020-18752-7] [PMID: 31911652]

Blümcke, I.; Luyken, C.; Urbach, H.; Schramm, J.; Wiestler, O.D. An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis. Acta Neuropathol., 2004, 107(5), 381-388.
[http://dx.doi.org/10.1007/s00401-004-0833-3] [PMID: 15034726]

Aronica, E.; Redeker, S.; Boer, K.; Spliet, W.G.M.; van Rijen, P.C.; Gorter, J.A.; Troost, D. Inhibitory networks in epilepsy-associated gangliogliomas and in the perilesional epileptic cortex. Epilepsy Res., 2007, 74(1), 33-44.
[http://dx.doi.org/10.1016/j.eplepsyres.2006.12.002] [PMID: 17267178]

Liu, X.; Zhang, B.; Jin, Z.; Yang, H.; Rao, Z. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature, 2020.

Amamuddy, O.S.; Verkhivker, G.M.; Bishop, O.T. Impact of emerging mutations on the dynamic properties the SARS-CoV-2 main protease: An in silico investigation. bioRxiv, 2020.

Faraggi, E.; Dunker, A.K.; Jernigan, R.L.; Kloczkowski, A. Entropy, fluctuations, and disordered proteins. Entropy (Basel), 2019, 21(8), 764.
[http://dx.doi.org/10.3390/e21080764] [PMID: 32336912]

Sparks, F.T.; Liao, Z.; Li, W.; Grosmark, A.; Soltesz, I.; Losonczy, A. Hippocampal adult-born granule cells drive network activity in a mouse model of chronic temporal lobe epilepsy. Nat. Commun., 2020, 11(1), 6138.
[http://dx.doi.org/10.1038/s41467-020-19969-2] [PMID: 33262339]

Knight, L.S.; Wenzel, H.J.; Schwartzkroin, P.A. Inhibition and interneuron distribution in the dentate gyrus of p35 knockout mice. Epilepsia, 2012, 53(Suppl. 1), 161-170.
[http://dx.doi.org/10.1111/j.1528-1167.2012.03487.x] [PMID: 22612821]

Denkena, J.; Zaisser, A.; Merz, B.; Klinger, B.; Kuhl, D.; Blüthgen, N.; Hermey, G. Neuronal activity regulates alternative exon usage. Mol. Brain, 2020, 13(1), 148.
[http://dx.doi.org/10.1186/s13041-020-00685-3] [PMID: 33172478]

Hermey, G.; Blüthgen, N.; Kuhl, D. Neuronal activity-regulated alternative mRNA splicing. Int. J. Biochem. Cell Biol., 2017, 91, 184-193.
[http://dx.doi.org/10.1016/j.biocel.2017.06.002] [PMID: 28591617]

Zygmunt, M.; Hoinkis, D.; Hajto, J.; Piechota, M. Skupień-Rabian, B.; Jankowska, U.; Kędracka-Krok, S.; Rodriguez Parkitna, J.; Korostyński, M. Expression of alternatively spliced variants of the Dclk1 gene is regulated by psychotropic drugs. BMC Neurosci., 2018, 19(1), 55.
[http://dx.doi.org/10.1186/s12868-018-0458-4] [PMID: 30208879]

Rodrigo-Domingo, M.; Waagepetersen, R.; Bødker, J.S.; Falgreen, S.; Kjeldsen, M.K.; Johnsen, H.E.; Dybkaer, K.; Bøgsted, M. Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor. Brief. Bioinform., 2014, 15(4), 519-533.
[http://dx.doi.org/10.1093/bib/bbt011] [PMID: 23603090]

Saito, H.; Kimura, M.; Inanobe, A.; Ohe, T.; Kurachi, Y. An N-terminal sequence specific for a novel Homer1 isoform controls trafficking of group I metabotropic glutamate receptor in mammalian cells. Biochem. Biophys. Res. Commun., 2002, 296(3), 523-529.
[http://dx.doi.org/10.1016/S0006-291X(02)00899-9] [PMID: 12176012]

Sapkota, D.; Lake, A.M.; Yang, W.; Yang, C.; Wesseling, H.; Guise, A.; Uncu, C.; Dalal, J.S.; Kraft, A.W.; Lee, J.M.; Sands, M.S.; Steen, J.A.; Dougherty, J.D. Cell-type-specific profiling of alternative translation identifies regulated protein isoform variation in the mouse brain. Cell Rep., 2019, 26(3), 594-607.e7.
[http://dx.doi.org/10.1016/j.celrep.2018.12.077] [PMID: 30650354]

Khan, H.N.; Kulsoom, S.; Rashid, H. Ligand based pharmacophore model development for the identification of novel antiepileptic compound. Epilepsy Res., 2012, 98(1), 62-71.
[http://dx.doi.org/10.1016/j.eplepsyres.2011.08.016] [PMID: 22071553]

Malawska, B.; Scatturin, A. Application of pharmacophore models for the design and synthesis of new anticonvulsant drugs. Mini Rev. Med. Chem., 2003, 3(4), 341-348.
[http://dx.doi.org/10.2174/1389557033488088] [PMID: 12678827]

Tasso, S.M.; Bruno-Blanch, L.E.; Moon, S.C.; Estiú, G.L. Pharmacophore searching and QSAR analysis in the design of anticonvulsant drugs. J. Mol. Struct. THEOCHEM, 2000, 504(1-3), 229-240.
[http://dx.doi.org/10.1016/S0166-1280(00)00364-X]

Siddiqui, N.; Ahsan, W.; Alam, M.S.; Ali, R.; Srivastava, K. Design, synthesis and evaluation of anticonvulsant activity of pyridinyl-pyrrolidones: A pharmacophore hybrid approach. Arch. Pharm. (Weinheim), 2012, 345(3), 185-194.
[http://dx.doi.org/10.1002/ardp.201100140] [PMID: 21997797]

Moore, Y.E.; Kelley, M.R.; Brandon, N.J.; Deeb, T.Z.; Moss, S.J. Seizing control of KCC2: A new therapeutic target for epilepsy. Trends Neurosci., 2017, 40(9), 555-571.
[http://dx.doi.org/10.1016/j.tins.2017.06.008] [PMID: 28803659]

Hartz, A.M.; Notenboom, S.; Bauer, B. Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy? Drug News Perspect., 2009, 22(7), 393-397.
[http://dx.doi.org/10.1358/dnp.2009.22.7.1401354] [PMID: 19890496]

Citraro, R.; Leo, A.; Constanti, A.; Russo, E.; De Sarro, G. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol. Res., 2016, 107, 333-343.
[http://dx.doi.org/10.1016/j.phrs.2016.03.039] [PMID: 27049136]

Walker, L.; Sills, G.J. Inflammation and epilepsy: The foundations for a new therapeutic approach in epilepsy? Epilepsy Curr., 2012, 12(1), 8-12.
[http://dx.doi.org/10.5698/1535-7511-12.1.8] [PMID: 22368518]

Willmore, L.J. Antiepileptic drugs and neuroprotection: Current status and future roles. Epilepsy Behav., 2005, 7(Suppl. 3), 25-28.
[http://dx.doi.org/10.1016/j.yebeh.2005.08.006] [PMID: 16239127]

Cohen, I.; Navarro, V.; Clemenceau, S.; Baulac, M.; Miles, R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science, 2002, 298(5597), 1418-1421.
[http://dx.doi.org/10.1126/science.1076510] [PMID: 12434059]

Kobow, K.; Auvin, S.; Jensen, F.; Löscher, W.; Mody, I.; Potschka, H.; Prince, D.; Sierra, A.; Simonato, M.; Pitkänen, A.; Nehlig, A.; Rho, J.M. Finding a better drug for epilepsy: Antiepileptogenesis targets. Epilepsia, 2012, 53(11), 1868-1876.
[http://dx.doi.org/10.1111/j.1528-1167.2012.03716.x] [PMID: 23061663]

Rogawski, M.A. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol. Scand., 2013, 127(197), 9-18.
[http://dx.doi.org/10.1111/ane.12099] [PMID: 23480151]

Ghasemi, M.; Schachter, S.C. The NMDA receptor complex as a therapeutic target in epilepsy: A review. Epilepsy Behav., 2011, 22(4), 617-640.
[http://dx.doi.org/10.1016/j.yebeh.2011.07.024] [PMID: 22056342]

Kaur, H.; Kumar, B.; Medhi, B. Antiepileptic drugs in development pipeline: A recent update. eNeurologicalSci, 2016, 4, 42-51.
[http://dx.doi.org/10.1016/j.ensci.2016.06.003] [PMID: 29430548]

Rogawski, M.A.; Bazil, C.W. New molecular targets for antiepileptic drugs: α2δ SV2A, and Kv7/KCNQ/M potassium channels. Curr. Neurol. Neurosci. Rep., 2008, 8(4), 345-352.
[http://dx.doi.org/10.1007/s11910-008-0053-7] [PMID: 18590620]

Rogawski, M.A. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res., 2006, 68(1), 22-28.
[http://dx.doi.org/10.1016/j.eplepsyres.2005.09.012] [PMID: 16377151]

Kambli, L.; Bhatt, L.K.; Oza, M.; Prabhavalkar, K. Novel therapeutic targets for epilepsy intervention. Seizure, 2017, 51, 27-34.
[http://dx.doi.org/10.1016/j.seizure.2017.07.014] [PMID: 28772199]

Johannessen Landmark, C. Antiepileptic drugs in non-epilepsy disorders: Relations between mechanisms of action and clinical efficacy. CNS Drugs, 2008, 22(1), 27-47.
[http://dx.doi.org/10.2165/00023210-200822010-00003] [PMID: 18072813]

Molecular and Cellular Targets for Antiepileptic Drugs; Avanzini, G., Ed.; John Libbey Eurotext: France, 1997.

Myers, K.A.; Scheffer, I.E. DEPDC5 as a potential therapeutic target for epilepsy. Expert Opin. Ther. Targets, 2017, 21(6), 591-600.
[http://dx.doi.org/10.1080/14728222.2017.1316715] [PMID: 28406046]

Giraud, C.; Tran, A.; Rey, E.; Vincent, J.; Tréluyer, J.M.; Pons, G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: Importance of CYP2C19. Drug Metab. Dispos., 2004, 32(11), 1279-1286.
[http://dx.doi.org/10.1124/dmd.32.11.1279] [PMID: 15483195]

Chiron, C.; Dulac, O. The pharmacologic treatment of Dravet syndrome. Epilepsia, 2011, 52(Suppl. 2), 72-75.
[http://dx.doi.org/10.1111/j.1528-1167.2011.03007.x] [PMID: 21463285]

Aneja, S.; Sharma, S. Newer anti-epileptic drugs. Indian Pediatr., 2013, 50(11), 1033-1040.
[http://dx.doi.org/10.1007/s13312-013-0284-9] [PMID: 24382900]

White, H.S. Preclinical development of antiepileptic drugs: Past, present, and future directions. Epilepsia, 2003, 44(Suppl. 7), 2-8.
[http://dx.doi.org/10.1046/j.1528-1157.44.s7.10.x] [PMID: 12919332]

Verrotti, A.; Loiacono, G.; Rossi, A.; Zaccara, G. Eslicarbazepine acetate: An update on efficacy and safety in epilepsy. Epilepsy Res., 2014, 108(1), 1-10.
[http://dx.doi.org/10.1016/j.eplepsyres.2013.10.005] [PMID: 24225327]

Almeida, L.; Soares-da-Silva, P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics, 2007, 4(1), 88-96.
[http://dx.doi.org/10.1016/j.nurt.2006.10.005] [PMID: 17199020]

Bonifácio, M.J.; Sheridan, R.D.; Parada, A.; Cunha, R.A.; Patmore, L.; Soares-da-Silva, P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: Comparison with carbamazepine. Epilepsia, 2001, 42(5), 600-608.
[http://dx.doi.org/10.1046/j.1528-1157.2001.43600.x] [PMID: 11380566]

Parikh, S.K.; Silberstein, S.D. Current status of antiepileptic drugs as preventive migraine therapy. Curr. Treat. Options Neurol., 2019, 21(4), 16.
[http://dx.doi.org/10.1007/s11940-019-0558-1] [PMID: 30880369]

Franco, V.; Crema, F.; Iudice, A.; Zaccara, G.; Grillo, E. Novel treatment options for epilepsy: Focus on perampanel. Pharmacol. Res., 2013, 70(1), 35-40.
[http://dx.doi.org/10.1016/j.phrs.2012.12.006] [PMID: 23287426]

Biton, V.; Berkovic, S.F.; Abou-Khalil, B.; Sperling, M.R.; Johnson, M.E.; Lu, S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double‐blind, placebo‐controlled trial. Epilepsia, 2014, 55(1), 57-66.
[http://dx.doi.org/10.1111/epi.12433] [PMID: 24446953]

Shih, J.; Tatum, W.O.; Rudzinski, L. New drug classes for the treatment of partial onset epilepsy: Focus on perampanel. Ther. Clin. Risk Manag., 2013, 9, 285-293.
[http://dx.doi.org/10.2147/TCRM.S37317] [PMID: 23874099]

Weisenberg, J.L.; Wong, M. Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures. Neuropsychiatr. Dis. Treat., 2011, 7, 409-414.
[PMID: 21792307]

Zaccara, G.; Giovannelli, F.; Cincotta, M.; Carelli, A.; Verrotti, A. Clinical utility of eslicarbazepine: Current evidence. Drug Des. Devel. Ther., 2015, 9, 781-789.
[http://dx.doi.org/10.2147/DDDT.S57409] [PMID: 25709402]

Hsu, K.; Whitham, E.; Kichenadasse, G. Potential role of cannabidiol for seizure control in a patient with recurrent glioma. J. Clin. Neurosci., 2020, 71, 275-276.
[http://dx.doi.org/10.1016/j.jocn.2019.11.024] [PMID: 31848037]

Freedman, M. Screening ultrasound after a first febrile UTI is not cost-effective. Contemp. Pediatr., 2020, 37(3), 7.

Hung, T.Y.; Huang, H.Y.; Wu, S.N.; Huang, C.W. Depressive effectiveness of vigabatrin (y-Vinyl-GABA), an antiepileptic drug, in intermediate-conductance calcium-activated potassium channels in human glioma cells. BMC Pharmacol. Toxicol., 2021, 22, 6.

Sawanny, R.; Bajetha, D.; Sharma, V.; Joshi, S.K. Epidemic 2019-20-covid-19 current scenario. World J. Pharm. Pharm. Sci., 2020, 9(6), 673-697.

Toth, C. Pregabalin: Latest safety evidence and clinical implications for the management of neuropathic pain. Ther. Adv. Drug Saf., 2014, 5(1), 38-56.
[http://dx.doi.org/10.1177/2042098613505614] [PMID: 25083261]

Witkin, J.M.; Ping, X.; Cerne, R.; Mouser, C.; Jin, X.; Hobbs, J.; Tiruveedhula, V.V.N.P.B.; Li, G.; Jahan, R.; Rashid, F.; Kumar Golani, L.; Cook, J.M.; Smith, J.L. The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81. Brain Res., 2019, 1722, 146356.
[http://dx.doi.org/10.1016/j.brainres.2019.146356] [PMID: 31369732]

Cramer, J.A.; Yan, T.; Tieu, R.; Knoth, R.L.; Fincher, C.; Malhotra, M.; Choi, J. Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs. Epilepsy Behav., 2020, 102, 106634.
[http://dx.doi.org/10.1016/j.yebeh.2019.106634] [PMID: 31783318]

Moseley, B.D.; Otoul, C.; Staelens, L.; Stockis, A. Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials. Epilepsy Res., 2019, 158, 106218.
[http://dx.doi.org/10.1016/j.eplepsyres.2019.106218] [PMID: 31675621]

Hertzberg, C.; Franz, D.N. Anticonvulsant agents: Everolimus. Neuro Psychopharmacotherapy, 2020, 2020, 1-32.

Samur, D.N.; Arslan, R. Aydın, S.; Bektas, N. Valnoctamide: The effect on relieving of neuropathic pain and possible mechanisms. Eur. J. Pharmacol., 2018, 827, 208-214.
[http://dx.doi.org/10.1016/j.ejphar.2018.03.006] [PMID: 29522726]

Qian, Z.M.; Ke, Y.; Huperzine, A. Is it an effective disease-modifying drug for Alzheimer’s disease? Front. Aging Neurosci., 2014, 6, 216.
[http://dx.doi.org/10.3389/fnagi.2014.00216] [PMID: 25191267]

Leclercq, K.; Matagne, A.; Provins, L.; Klitgaard, H.; Kaminski, R.M. Pharmacological profile of the novel antiepileptic drug candidate padsevonil: Characterization in rodent seizure and epilepsy models. J. Pharmacol. Exp. Ther., 2020, 372(1), 11-20.
[http://dx.doi.org/10.1124/jpet.119.261222] [PMID: 31619464]

Kasteleijn-Nolst Trenité, D.G.A.; Biton, V.; French, J.A.; Abou-Khalil, B.; Rosenfeld, W.E.; Diventura, B.; Moore, E.L.; Hetherington, S.V.; Rigdon, G.C.K. v7 potassium channel activation with ICA ‐105665 reduces photoparoxysmal EEG responses in patients with epilepsy. Epilepsia, 2013, 54(8), 1437-1443.
[http://dx.doi.org/10.1111/epi.12224] [PMID: 23692516]

Nazar, S.; Siddiqui, N.; Alam, O. Recent progress of 1,3,4‐oxadiazoles as anticonvulsants: Future horizons. Arch. Pharm. (Weinheim), 2020, 353(7), 1900342.
[http://dx.doi.org/10.1002/ardp.201900342] [PMID: 32319117]